These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 27854156)

  • 1. Demonstration of physicochemical and functional similarity between the proposed biosimilar adalimumab MSB11022 and Humira®.
    Magnenat L; Palmese A; Fremaux C; D'Amici F; Terlizzese M; Rossi M; Chevalet L
    MAbs; 2017 Jan; 9(1):127-139. PubMed ID: 27854156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab.
    Schreiber S; Yamamoto K; Muniz R; Iwura T
    Pharmacol Res Perspect; 2020 Jun; 8(3):e00604. PubMed ID: 32500668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira
    Lee JJ; Yang J; Lee C; Moon Y; Ahn S; Yang J
    Biologicals; 2019 Mar; 58():7-15. PubMed ID: 30744947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects.
    Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V
    Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab.
    Lee N; Lee JJ; Yang H; Baek S; Kim S; Kim S; Lee T; Song D; Park G
    MAbs; 2019 Jan; 11(1):129-144. PubMed ID: 30296198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical and Functional Characterization of HS016, a Biosimilar of Adalimumab (Humira).
    Gao D; Nie L; Yuan J; Hu F; Wu Z; Lin Q; Wang H
    J Pharm Sci; 2022 Apr; 111(4):1142-1151. PubMed ID: 34863972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality by Design-Based Assessment for Analytical Similarity of Adalimumab Biosimilar HLX03 to Humira®.
    Zhang E; Xie L; Qin P; Lu L; Xu Y; Gao W; Wang L; Xie MH; Jiang W; Liu S
    AAPS J; 2020 May; 22(3):69. PubMed ID: 32385732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®).
    Kwon JC; Kwon OH; Jeong RU; Kim N; Song S; Choi I; Lee J; Horiuchi T
    Anim Cells Syst (Seoul); 2021; 25(3):182-194. PubMed ID: 34262661
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of adalimumab biosimilar MSB11022 (acetate-buffered formulation) in patients with moderately-to-severely active rheumatoid arthritis.
    Edwards CJ; Monnet J; Ullmann M; Vlachos P; Chyrok V; Ghori V
    Clin Rheumatol; 2019 Dec; 38(12):3381-3390. PubMed ID: 31396834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The totality of evidence approach in the development of AVT02 (adalimumab), a biosimilar to Humira.
    McClellan JE; Ómarsdóttir S; Roy N; Berger V; Michel C; Berti F
    Ther Adv Chronic Dis; 2024; 15():20406223231223286. PubMed ID: 38250743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab.
    Jiang Y; Arora T; Klakamp S; Davis J; Chandrasekher YA; Young G; Du Y; Yu B; Miller KJ
    Drugs R D; 2023 Dec; 23(4):377-395. PubMed ID: 37632627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE®-PK) in healthy subjects.
    Wynne C; Altendorfer M; Sonderegger I; Gheyle L; Ellis-Pegler R; Buschke S; Lang B; Assudani D; Athalye S; Czeloth N
    Expert Opin Investig Drugs; 2016 Dec; 25(12):1361-1370. PubMed ID: 27813422
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects.
    Puri A; Niewiarowski A; Arai Y; Nomura H; Baird M; Dalrymple I; Warrington S; Boyce M
    Br J Clin Pharmacol; 2017 Jul; 83(7):1405-1415. PubMed ID: 28133772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis.
    Gisondi P; Geat D; Armeni P; Bellinato F; Maurelli M; Girolomoni G
    Expert Opin Biol Ther; 2022 Dec; 22(12):1579-1584. PubMed ID: 35466843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
    Park D; Yun J; Hwang SJ; Park SJ
    Adv Ther; 2019 Feb; 36(2):442-450. PubMed ID: 30554330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
    Wang Y; Gao Z; Liu Z; Liu G; Qu X; Chen J; Ren X; Xu Z; Yang H
    Expert Opin Biol Ther; 2022 Feb; 22(2):225-234. PubMed ID: 34134579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G; Gilardi D; Correale C; Furfaro F; Roda G; Loy L; Argollo M; Allocca M; Peyrin-Biroulet L; Danese S
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [No Abstract]   [Full Text] [Related]  

  • 19. Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
    Coghlan J; He H; Schwendeman AS
    J Pharm Sci; 2021 Apr; 110(4):1572-1582. PubMed ID: 33556387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.
    Hillson J; Mant T; Rosano M; Huntenburg C; Alai-Safar M; Darne S; Palmer D; Pavlova BG; Doralt J; Reeve R; Goel N; Weilert D; Rhyne PW; Chance K; Caminis J; Roach J; Ganguly T
    Pharmacol Res Perspect; 2018 Feb; 6(1):. PubMed ID: 29417761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.